MyoKardia_Logo_RGB.png
MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries
June 19, 2020 08:30 ET | MyoKardia, Inc.
-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that data from...
MyoKardia_Logo_RGB.png
MyoKardia to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
June 16, 2020 08:00 ET | MyoKardia, Inc.
BRISBANE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the virtual...
MyoKardia_Logo_RGB.png
MyoKardia Announces Pricing of Public Offering of Common Stock
May 12, 2020 21:34 ET | MyoKardia, Inc.
BRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia Announces Proposed Public Offering of Common Stock
May 11, 2020 16:02 ET | MyoKardia, Inc.
BRISBANE, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
May 11, 2020 07:30 ET | MyoKardia, Inc.
Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo Mavacamten Well Tolerated; Safety Results Comparable to Placebo U.S. Regulatory...
MyoKardia_Logo_RGB.png
MyoKardia Reports First Quarter 2020 Financial Results
May 06, 2020 16:05 ET | MyoKardia, Inc.
BRISBANE, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the first quarter ended March 31, 2020. “Our team has continued to drive...
MyoKardia_Logo_RGB.png
MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients
March 30, 2020 10:30 ET | MyoKardia, Inc.
MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten Improvement in NT-proBNP and Troponin Levels Support Future Development in...
MyoKardia_Logo_RGB.png
MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic
March 26, 2020 08:30 ET | MyoKardia, Inc.
BRISBANE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today provided an update to the status of its clinical programs in the context of the COVID-19 (coronavirus)...
MyoKardia_Logo_RGB.png
Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology
March 19, 2020 16:45 ET | MyoKardia, Inc.
BRISBANE, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will be presenting data from its Phase 2 MAVERICK-HCM clinical trial during a...
MyoKardia_Logo_RGB.png
MyoKardia Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020 16:05 ET | MyoKardia, Inc.
BRISBANE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the fourth quarter and full year ended December 31, 2019. “MyoKardia...